首页>
外国专利>
Nonoxidative, biologically active parathyroid hormone determines mortality in hemodialysis patients
Nonoxidative, biologically active parathyroid hormone determines mortality in hemodialysis patients
展开▼
机译：非氧化性，生物活性甲状旁腺激素决定了血液透析患者的死亡率
展开▼
页面导航
摘要
著录项
相似文献
摘要
A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. Figure 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt/V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other/unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng/L (IQR, 2.4 to 14.0 ng/L). n-oxPTH concentrations were not different in men and women (5.9 ng/L; IQR, 2.4 to 14.2 ng/L; n = 224; vs. 5.5 ng/L; IQR, 2.4 to 14.0 ng/L; n = 116; p = 0.915).
展开▼
机译：一种新的体外监测和评估药物需求的新方法，该药物会干扰患有氧化应激的肾病患者，尤其是血液透析患者的甲状旁腺激素水平。图1显示了340位血液透析患者（224位男性和116位女性）的n-oxPTH浓度分布，中位年龄为66岁（IQR，56至75岁），这是自开始透析（透析期）以来的中位时间为266岁（IQR，31至1209天），平均透析剂量（kt / V）为1.2（IQR，1.1至1.3）。慢性肾脏病的病因是肾硬化113例（33％），糖尿病肾病107例（31％），慢性肾小球肾炎29例（9％），多囊肾9例（3％）和其他/未知82例（24％）。 n-oxPTH的中位浓度为5.9 ng / L（IQR，2.4至14.0 ng / L）。男性和女性的n-oxPTH浓度无差异（5.9 ng / L; IQR，2.4至14.2 ng / L; n = 224; vs. 5.5 ng / L; IQR，2.4至14.0 ng / L; n = 116; p = 0.915）。
展开▼
